News
CABA
2.165
-2.48%
-0.055
H.C. Wainwright Keeps Their Buy Rating on Cabaletta Bio (CABA)
TipRanks · 3d ago
Weekly Report: what happened at CABA last week (0914-0918)?
Weekly Report · 3d ago
Cabaletta Bio Boosts Cash Through Warrant Exercises
TipRanks · 09/14 12:31
Weekly Report: what happened at CABA last week (0907-0911)?
Weekly Report · 09/14 09:10
Weekly Report: what happened at CABA last week (0831-0904)?
Weekly Report · 09/07 09:09
Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Cabaletta Bio (CABA)
TipRanks · 09/02 15:10
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Medtronic (MDT)
TipRanks · 09/02 11:10
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 09/02 07:40
Cabaletta Bio (CABA) Receives a Hold from Wells Fargo
TipRanks · 09/01 23:15
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 09/01 12:02
Weekly Report: what happened at CABA last week (0824-0828)?
Weekly Report · 08/31 09:10
Weekly Report: what happened at CABA last week (0817-0821)?
Weekly Report · 08/24 09:10
We're Keeping An Eye On Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Simply Wall St · 08/20 10:16
Weekly Report: what happened at CABA last week (0810-0814)?
Weekly Report · 08/17 09:10
Cabaletta Bio reports Q2 EPS (34c), consensus (34c)
TipRanks · 08/17 07:57
Adicet Bio: A Cheap Gamma Delta T-Cell Play
Seeking Alpha · 08/14 17:18
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 08/14 14:55
Cabaletta Bio Price Target Cut to $3.00/Share From $4.00 by Wells Fargo
Dow Jones · 08/14 14:55
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Benzinga · 08/14 14:46
Cabaletta Bio (CABA) Gets a Buy from Cantor Fitzgerald
TipRanks · 08/14 12:56
More
Webull provides a variety of real-time CABA stock news. You can receive the latest news about Cabaletta Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.